Search Results for: CANCER IMMUNOTHERAPY Building on Initial
Articles
CANCER IMMUNOTHERAPY - Building on Initial Successes to Improve Clinical Outcomes November 20, 2017
Allan B. Haberman, PhD, provides an updated discussion of approved and clinical-stage agents in immuno-oncology, including recently approved agents. He also addresses how researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients.
THERAPEUTIC FOCUS - Addressing the Unmet Need for Improved Treatments of Female Cancers January 16, 2023
Martin Lehr, MA, explains how his company is advancing a pipeline of innovative products designed to address treatment resistance in breast, ovarian, and endometrial cancer, which, if approved, could provide patients with a much-needed new treatment options.
Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept January 30, 2020
Avacta Group plc recently announced it has demonstrated initial proof-of-concept for its proprietary new class of drug conjugate, TMAC, in...BioNTech & DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate January 31, 2024
BioNTech SE and Duality Biologics recently announced the US FDA granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer….
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
BioNTech & Crescendo Biologics Announce Global Collaboration to Develop Multi-Specific Precision Immunotherapies January 10, 2022
BioNTech SE and Crescendo Biologics Ltd. recently announced they have entered a multi-target discovery collaboration to develop novel immunotherapies for the...ARTIFICIAL INTELLIGENCE - Attempting to Speed Up Vaccine Development to Combat the Next Pandemic October 4, 2021
Lars Wegner, MD, in the wake of the huge impact Covid-19 has had around the world, presents a state-of-the-art mathematical modelling and algorithms approach to vaccine development to prevent the next pandemic.
TriSalus Life Sciences & Roger Williams Medical Center Announce Initiation of Phase 1 Clinical Trial for a Novel Delivery Technology February 14, 2020
TriSalus Life Sciences recently announced the initiation of a new clinical trial assessing the safety and feasibility of an innovative new treatment that combines its…..
LDC & SOTIO Enter License & Collaboration Agreement April 17, 2017
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI), and SOTIO a.s. have signed a collaboration and license...DNA VACCINE TECHNOLOGY - A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs August 31, 2015
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
CiMaas & PharmaCell BV Enter Collaborative Agreement July 14, 2015
CiMaas BV, a company developing cellular immunotherapy for cancer, and PharmaCell BV, a leading Contract Manufacturing Organization for Cellular Therapies...Juno Therapeutics Raises IPO Target to $191 Million December 16, 2014
Seattle cancer-immunotherapy company Juno Therapeutics recently announced it has upped the target for its pending initial public offering of stock...12/6/2011 December 4, 2011
Nanion's SyncroPatch 96 Convinces Big Pharma Automated Patch Clamp Users Nanion's ion channel screening platform, the SyncroPatch 96, has been...
